News >

FDA Delays Decision on Lenvatinib for HCC

Silas Inman @silasinman
Published: Friday, May 25, 2018

Masatoshi Kudo, MD
Masatoshi Kudo, MD
The FDA has extended the review period for lenvatinib (Lenvima) as a first-line treatment for patients with unresectable hepatocellular carcinoma (HCC), to allow ample time to review the application, according to Eisai and Merck, the companies codeveloping the drug. The new action date for the supplemental new drug application (sNDA) is August 24, 2018.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication
x